Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00916058 · ClinicalTrials.gov registry record · Phase 1
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT00916058 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 57 participants.
The verdict
NCT00916058, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of Bendamustine (TREANDA™), in combination with Melphalan in subjects with multiple myeloma who are undergoing an Autologous Stem Cell Transplant.
Interventions
- DRUG Melphalan
- DRUG Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2009-04-23 |
| Est. Completion | 2018-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00916058
The ClinicalTrials.gov registry entry for NCT00916058 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Melphalan is the first listed.
NCT00916058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00916058 about?
NCT00916058 is a clinical study titled "Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma". The purpose of this study is to evaluate the safety and efficacy of Bendamustine (TREANDA™), in combination with Melphalan in subjects with multiple myeloma who are undergoing an Autologous Stem Cell Transplant.
What is the current status of trial NCT00916058?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2009-04-23. Estimated completion is 2018-03-01.
What interventions are being tested in trial NCT00916058?
The interventions under investigation include: Melphalan (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT00916058?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.